Healthcare - Biotechnology - NASDAQ - US
$ 6.53
-8.16 %
$ 237 M
Market Cap
-1.62
P/E
CASH FLOW STATEMENT
-96.6 M
OPERATING CASH FLOW
-2.22 M
INVESTING CASH FLOW
164 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Biomea Fusion, Inc.
| Net Income | -117 M |
| Depreciation & Amortization | 4.2 M |
| Capital Expenditures | -3.37 M |
| Stock-Based Compensation | 14.1 M |
| Change in Working Capital | 2.33 M |
| Others | 19.7 M |
| Free Cash Flow | -100 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (117.3) | (81.8) | (41.6) | (5.3) | (1.2) |
| Depreciation & Amortization | 4.2 | 0.7 | 0.2 | 8 K | 0 |
| Deferred Income Tax | 0 | 0 | 0.5 | 0 | 0 |
| Stock Based Compensation | 14.1 | 10.3 | 6.2 | 0.3 | 0 |
| Other Operating Activities | 20.0 | 0.7 | 0.7 | 0.1 | 98 K |
| Change in Working Capital | 2.3 | 7.7 | (1.6) | 0.4 | 81 K |
| Cash From Operations | (96.6) | (62.4) | (35.4) | (4.5) | (1.3) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (3.4) | (1.0) | (3.2) | 51 K | 0 |
| Other Items | 1.1 | 28.4 | (30.2) | 0 | 0 |
| Cash From Investing Activities | (2.2) | 27.3 | (33.4) | 51 K | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 36 K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.0 | 1.2 | 153.2 | 121.7 | 0 |
| Cash From Financing Activities | 163.8 | 1.2 | 153.2 | 66.0 | 1.4 |
| CHANGE IN CASH | |||||
| Net Change In Cash | 65.0 | (33.8) | 84.4 | 61.5 | 0.2 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (100.0) | (63.4) | (38.6) | (4.5) | (1.3) |